Biodesix Inc
BDSX Nasdaq· Services-Medical Laboratories
Last close · Oct 23, 2026
$21.18
KIRA · Stoqly’s AI analyst, in plain words
- Biodesix Inc had $88.5M of revenue in fiscal 2025, up 24.1% on the year before. Over five years, revenue changed +14.2% a year on average.
- Its operating margin was −31.5%, up 16.9 pts: of every 100 in sales, about −31 is left after running the business.
- Biodesix Inc lost $35.3M in fiscal 2025.
- Free cash flow was −$23.5M in fiscal 2025, −26.6% of revenue.
- Biodesix Inc owes $31.0M more than it holds in cash.
Market cap
$218M
P/E
—
Revenue
$88.5M
Net income
−$35.3M
Free cash flow
−$23.5M
Operating margin
−31.5%
Biodesix Inc in 30 seconds · fiscal 2025
Are sales growing?
+24.1%
Yes. Sales grew 24.1% last year.
Does it make a profit?
−39.8%
No. It lost money last year.
Does profit turn into cash?
−26.6%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Biodesix Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- BIODESIX INC
- CIK
- 0001439725
Biodesix Inc · BDSX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $54.5M | $38.2M | $49.1M | $71.3M | $88.5M |
| Revenue growth | 19.6% | −29.9% | 28.5% | 45.3% | 24.1% |
| Operating margin | −75.1% | −132.4% | −84.2% | −48.4% | −31.5% |
| Net income | −$43.2M | −$65.4M | −$52.1M | −$42.9M | −$35.3M |
| Net margin | −79.2% | −171.3% | −106.2% | −60.2% | −39.8% |
| Diluted EPS | −$1.58 | −$1.55 | −$0.64 | −$6.64 | −$4.67 |
| Cash | |||||
| Cash from operations | −$28.2M | −$45.0M | −$22.9M | −$48.6M | −$23.3M |
| Capital expenditure | $2.2M | $3.3M | $22.9M | $3.2M | $0.3M |
| Free cash flow | −$30.5M | −$48.3M | −$45.8M | −$51.9M | −$23.5M |
| FCF margin | −55.9% | −126.3% | −93.3% | −72.7% | −26.6% |
| Share count change | 465.6% | 53.9% | 95.0% | −92.1% | 16.7% |
| Debt and strength | |||||
| Cash and short-term investments | $32.7M | $43.1M | $26.3M | $26.2M | $19.0M |
| Debt incl. finance leases | $10.1M | $30.1M | $40.1M | $40.0M | $50.0M |
| Shareholders' equity | $19.7M | $20.6M | $4.6M | $20.9M | −$2.5M |
| Current ratio | 1.5x | 2.3x | 1.2x | 2.8x | 1.9x |
| Interest coverage | −9.1x | −6.3x | −4.3x | −4.2x | −3.6x |
| Returns and quality | |||||
| Return on capital | — | −522.7% | −177.8% | −78.6% | −77.1% |
| Return on equity | −141.8% | −324.5% | −414.1% | −337.3% | −383.1% |
| Piotroski F-score | 3 | 2 | 3 | 4 | 3 |
| Altman Z'' | −14.9 | −14.1 | −16.1 | −15.9 | −19.6 |
Insiders bought, 12 months
$3.1M
1 insider
Insiders sold, 12 months
$0.1M
5 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Biodesix Inc · BDSX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $21.18 a share, the company is worth $218M.
Source: SEC EDGAR XBRL filings (CIK 0001439725). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.